JPS6125381B2 - - Google Patents
Info
- Publication number
- JPS6125381B2 JPS6125381B2 JP52002989A JP298977A JPS6125381B2 JP S6125381 B2 JPS6125381 B2 JP S6125381B2 JP 52002989 A JP52002989 A JP 52002989A JP 298977 A JP298977 A JP 298977A JP S6125381 B2 JPS6125381 B2 JP S6125381B2
- Authority
- JP
- Japan
- Prior art keywords
- ascites
- membrane
- pass
- filtration
- membranes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000012528 membrane Substances 0.000 claims description 64
- 206010003445 Ascites Diseases 0.000 claims description 41
- 238000001914 filtration Methods 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 17
- 201000011510 cancer Diseases 0.000 claims description 17
- 238000000108 ultra-filtration Methods 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- 241000894006 Bacteria Species 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 8
- 239000003792 electrolyte Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 9
- 229920000049 Carbon (fiber) Polymers 0.000 description 7
- 239000004917 carbon fiber Substances 0.000 description 7
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 5
- 125000006850 spacer group Chemical group 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 102000006395 Globulins Human genes 0.000 description 3
- 108010044091 Globulins Proteins 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000007599 discharging Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000011295 pitch Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Description
【発明の詳細な説明】
この発明は孔径を異にする２種類の半透性膜を
有する腹水処理用の流体処理装置に関する。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a fluid treatment device for treating ascites having two types of semipermeable membranes with different pore sizes.
近年、半透膜による透析、逆浸透、限外濾過、
膜濾過等の現象を利用して、膜を通して物質を移
動させる透析器、濾過器、濃縮器などの装置が
種々開発されている。 In recent years, dialysis using semipermeable membranes, reverse osmosis, ultrafiltration,
Various devices such as dialyzers, filters, and concentrators have been developed that utilize phenomena such as membrane filtration to move substances through membranes.
医療分野においても、たとえば血液の浄化装置
（人工腎臓、人工肺、人工肝臓など）や腹水の処
理装置として、膜を利用した流体処理器が用いら
れている。しかしながら、これら従来のものは、
１つの処理器が同一グレードの複数の膜により構
成されているので、機能の異なつた処理が一度に
できないうらみがあつた。 In the medical field, fluid treatment devices using membranes are used, for example, as blood purification devices (artificial kidneys, artificial lungs, artificial livers, etc.) and ascites treatment devices. However, these conventional methods
Since one processing device is composed of a plurality of membranes of the same grade, there is a problem that processing with different functions cannot be performed at the same time.
その一例をあげると、腹水処理装置において
は、腹水を抜き取つたのちまず腹水中の細菌、癌
細胞等生体にとつて有害な物質を濾過膜により除
去し、つぎに生体にとつて有用な蛋白質を濃縮膜
により濃縮して生体へ戻してやらなければならな
かつた。すなち、濾過器で細菌や癌細胞を除去し
た後市販の人工腎臓等を応用して濃縮する方法で
ある。 For example, in an ascites treatment device, after removing ascites, bacteria, cancer cells, and other substances harmful to living organisms in the ascites are first removed using a filtration membrane, and then proteins useful to living bodies are removed. had to be concentrated using a concentrating membrane and returned to the living body. In other words, bacteria and cancer cells are removed using a filter, and then concentrated using a commercially available artificial kidney.
したがつて、装置の組み立て、滅菌、腹水循環
回路の接続等に多大の労力を必要とするうえ、形
状寸法も大きくなり、使用上の問題点が多かつ
た。 Therefore, a great deal of labor is required for assembling the device, sterilizing it, connecting the ascites circulation circuit, etc., and the shape and dimensions are also large, resulting in many problems in use.
そこで我々は、これらの問題点を解決するため
に鋭意研究を行つた結果、本発明を得るにいたつ
た。 Therefore, as a result of intensive research to solve these problems, we have arrived at the present invention.
すなわちこの発明は、蛋白質を透過し、細菌、
癌細胞を透過しない過膜と、電解質を透過し、
蛋白質を透過しない限外過膜とが密閉容器内に
お互いにその片面を対向させて設置されて１つの
部屋を形成し、おのおのの膜のもう一方の面は容
器の壁または液体不透過性物質との間にそれぞれ
独立した部屋を形成しており、上記した３つの独
立した部屋は、それぞれ上記容器外へ導かれた少
なくとも１つの流体出入口を有することを特徴と
する腹水処理用の流体処理装置である。 In other words, this invention can penetrate proteins, bacteria,
Transmembrane that does not pass through cancer cells and allows electrolytes to pass through,
Protein-impermeable ultrafiltration membranes are placed in a closed container with one side facing each other to form a chamber, and the other side of each membrane is connected to the wall of the container or a liquid-impermeable material. A fluid treatment device for treating ascites, characterized in that each of the three independent chambers has at least one fluid inlet/outlet led to the outside of the container. It is.
以下、この発明を図面によつて説明する。第１
図はこの発明の一例を示す分解斜視図であり、第
２図は第１図の例を組み立てたときの正面断面図
であり、第３図は炭素繊維を組み込んだ例の正面
断面図であり、第４図は膜を円柱状に巻いた例の
模式図である。 The present invention will be explained below with reference to the drawings. 1st
The figure is an exploded perspective view showing an example of the present invention, FIG. 2 is a front sectional view of the assembled example of FIG. 1, and FIG. 3 is a front sectional view of an example incorporating carbon fiber. , FIG. 4 is a schematic diagram of an example in which the membrane is rolled into a cylindrical shape.
第１図および第２図の例は上蓋１、パツキン
２、半透膜３、パツキン４、半透膜３と孔径を異
にする半透膜５、下蓋６から構成されていて、上
蓋１、パツキン４、下蓋６にはそれぞれ流体の出
入口７，８，９，１０が取り付けられている。 The example shown in FIGS. 1 and 2 is composed of an upper lid 1, a packing 2, a semipermeable membrane 3, a packing 4, a semipermeable membrane 5 having a different pore size from the semipermeable membrane 3, and a lower lid 6. , the gasket 4, and the lower lid 6 are provided with fluid inlets and outlets 7, 8, 9, and 10, respectively.
以下、腹水処理に用いられる場合を例にとつて
説明すると、孔径の異なる２種類の半透膜として
は、除菌、除癌細胞用の濾過膜と、腹水濃縮用の
限外濾過膜が用いられる。この装置において、ま
ず、腹水は入口８から導入され、除菌、除癌細胞
用の濾過膜３と腹水を濃縮する限外濾過膜５に囲
まれた部屋に入る。すると、腹水中の電解質、水
等の低分子量物質は限外濾過膜５を通して出口１
０から排出され、濃縮されたアルブミン、グロブ
リン等の蛋白質が除菌、除癌細胞用の濾過膜３を
透過して出口７から導出される。どちらの膜も透
過しない細菌、癌細胞等の物質は、濾過膜３およ
び５に囲まれた部屋に溜まつてくる。これらの物
質は濾過膜３，５の濾過効率を低下させるので、
時折フラツシユ口９より除去する。このように、
腹水の濾過と濃縮が一つの処理器内で行われる。 Below, we will explain the case where it is used for ascites treatment as an example. Two types of semipermeable membranes with different pore sizes are used: a filtration membrane for eradicating bacteria and cancer-killing cells, and an ultrafiltration membrane for concentrating ascites. It will be done. In this device, ascites is first introduced through an inlet 8 and enters a room surrounded by a filtration membrane 3 for sterilization and cancer removal and an ultrafiltration membrane 5 for concentrating ascites. Then, low molecular weight substances such as electrolytes and water in the ascites pass through the ultrafiltration membrane 5 to the outlet 1.
0 and concentrated proteins such as albumin and globulin pass through the filter membrane 3 for sterilization and cancer removal cells and are led out from the outlet 7. Substances such as bacteria and cancer cells that do not pass through either membrane accumulate in the chamber surrounded by the filter membranes 3 and 5. These substances reduce the filtration efficiency of the filter membranes 3 and 5,
It is removed from the flash port 9 from time to time. in this way,
Filtration and concentration of ascites are performed in one processor.
ここで、除菌、除癌細胞用の濾過膜３とは、ア
ルブミン、グロブリン等の蛋白質、または、これ
より低分子量の物質は透過させるが、細菌、癌細
胞等は透過させない膜であり、セルロースアセテ
ートの膜等が使用できる。腹水を濃縮する限外濾
過膜５とは電解質、水等の低分子量の物質は透過
させるが、蛋白質またはこれより高分子量の物質
は透過させない膜であり、たとえばポリアクリロ
ニトリルの膜等が使用できる。また、上記濾過濃
縮器において腹水入口８、腹水出口７、フラツシ
ユ口９、濃液排出口１０は、それぞれ複数であつ
ても良い。 Here, the filtration membrane 3 for eradicating bacteria and removing cancer cells is a membrane that allows proteins such as albumin and globulin, or substances with a lower molecular weight to pass through, but does not allow bacteria, cancer cells, etc. to pass through. Acetate membrane etc. can be used. The ultrafiltration membrane 5 for concentrating ascites is a membrane that allows low molecular weight substances such as electrolytes and water to pass through, but does not allow proteins or higher molecular weight substances to pass through. For example, a polyacrylonitrile membrane can be used. Moreover, in the above-mentioned filtration concentrator, there may be a plurality of ascites inlets 8, ascites outlets 7, flush ports 9, and concentrated liquid discharge ports 10.
この腹水処理用濾過濃縮器は、第２図の様に組
み立ててから上蓋１と下蓋６の間にボルト（図示
しない）を入れて固定してもよいし、接着しても
良い。要は、液が容器外に洩れなければどんな方
法で固定しても良い。 This filtration/concentrator for treating ascites may be assembled as shown in FIG. 2 and then fixed by inserting bolts (not shown) between the upper lid 1 and the lower lid 6, or may be secured by adhesive. In short, any method can be used to fix the container as long as the liquid does not leak out of the container.
第１図、第２図に示した例において、腹水を腹
水出口７から入れても使用できる。ただし、この
場合、フラツシユ口９は上蓋１に取り付けておか
なければならない。導入された腹水は濾過膜３で
濾過、除菌、除癌細胞され、限外濾過膜５により
濃縮され、８で示す口より濃縮された蛋白溶液が
得られる。 In the example shown in FIGS. 1 and 2, it can be used even if ascites is introduced through the ascites outlet 7. However, in this case, the flash port 9 must be attached to the top lid 1. The introduced ascites is filtered through a filter membrane 3 to remove bacteria and cancerous cells, and concentrated through an ultrafiltration membrane 5. A concentrated protein solution is obtained from the port shown at 8.
また、膜と蓋の間、膜と膜の間の空間にスペー
サーを入れれば膜の破損、濾過効率の低下等が防
げる。さらに、この構造の物を多層に重ねたり、
渦状に巻いたりすることによつて、処理能力の高
い、小型の腹水処理用濾過濃縮器が得られる。 Furthermore, by inserting a spacer in the space between the membrane and the lid, or between the membranes, damage to the membrane and reduction in filtration efficiency can be prevented. Furthermore, things with this structure can be stacked in multiple layers,
By winding it into a spiral, a small-sized filtration concentrator for treating ascites with high throughput can be obtained.
腹水処理用の場合は、濾過濃縮器を構成する素
材はすべて、特に腹水に接触する素材はすべて、
人体に対して、無毒、無害にものでなければなら
ない。 For ascites treatment, all materials that make up the filtration concentrator, especially those that come into contact with ascites, must be
It must be non-toxic and harmless to the human body.
第３図は、活性炭を組み込んだ腹水の濾過濃縮
器の例であり、上蓋１１、除菌、除癌細胞用の濾
過膜に、腹水濃縮用の限外濾過膜１３、下蓋１
４、接着剤１５、スペーサ１６，１７、炭素繊維
１８とより構成されていて、上蓋１１には除菌、
除癌細胞され、さらに濃縮された腹水の出口１９
が取り付けられ、接着剤１５には、膜１２，１３
に囲まれた部屋に通じる腹水入口２０およびフラ
ツシユ口２１が取り付けられ、下蓋１４には限外
濾過膜１３からの濾液を排出するための出口２２
が取り付けられている。 FIG. 3 shows an example of an ascites filtration and concentrator incorporating activated carbon, including an upper lid 11, a filtration membrane for sterilization and cancer-killing cells, an ultrafiltration membrane 13 for concentrating ascites, and a lower lid 1.
4. Consists of adhesive 15, spacers 16, 17, and carbon fiber 18, and the upper lid 11 has sterilization,
Exit of ascitic fluid with cancer-free cells and further concentration 19
is attached to the adhesive 15, and the membranes 12, 13 are attached to the adhesive 15.
An ascites inlet 20 and a flush port 21 are attached to the lower lid 14 leading to a room surrounded by an ascites, and an outlet 22 for discharging the filtrate from the ultrafiltration membrane 13 is attached to the lower lid 14.
is installed.
この濾過濃縮器において、腹水は入口２０から
導入され、除菌、除癌細胞用の濾過膜１２と腹水
を濃縮する限外濾過膜１３に囲まれた部屋に入
る。すると、腹水中の電解質、水等の低分子量物
質は限外濾過膜１３を通して出口２２から排出さ
れ、濃縮されたアルブミン、グロブリン等の蛋白
質が除菌、除癌細胞用の濾過膜１２を透過して出
口１９から導出される。この過程で腹水は、炭素
繊維１８に接触し、濾過膜１２を透過してしまう
ようなパイロジエン物質等が吸着除去されるた
め、濃縮されて出口１９に導かれた濃縮蛋白質に
は、生体に有害な物質が含まれない。また、炭素
繊維１８はスペーサーとしても働いている。炭素
繊維の代わりに粒状、粉状の活性炭（ヤシガラ
炭、木炭、ピツチ系球状炭等）も使用できるが、
製造の容易さから繊維状の活性炭が望ましい。ま
た、活性炭の位置は第３図の位置でなくても蛋白
質を含んだ腹水が接触する位置であれば良い。こ
の場合使用される活性炭は人体に対して無毒、無
害なものでなければならない。 In this filtration concentrator, ascites is introduced through an inlet 20 and enters a room surrounded by a filtration membrane 12 for sterilizing and removing cancerous cells and an ultrafiltration membrane 13 for concentrating ascites. Then, low molecular weight substances such as electrolytes and water in the ascites pass through the ultrafiltration membrane 13 and are discharged from the outlet 22, and concentrated proteins such as albumin and globulin pass through the filtration membrane 12 for sterilization and cancer removal cells. and is led out from the outlet 19. During this process, the ascites comes into contact with the carbon fibers 18, and pyrogen substances that would otherwise pass through the filtration membrane 12 are adsorbed and removed, so that the concentrated proteins that are concentrated and led to the outlet 19 are harmful to living organisms. Contains no substances. Further, the carbon fiber 18 also functions as a spacer. Granular or powdered activated carbon (coconut husk charcoal, charcoal, pitch-based spherical charcoal, etc.) can also be used instead of carbon fiber.
Fibrous activated carbon is preferred because of its ease of manufacture. Furthermore, the activated carbon does not need to be placed at the position shown in FIG. 3, as long as it comes into contact with ascites containing protein. The activated carbon used in this case must be non-toxic and harmless to the human body.
第４図は濾過膜を渦巻状に巻き円柱形にし、円
筒容器に納めた腹水の濾過濃縮器の例の模式図で
あるが、円筒容器２３、除菌、除癌細胞用の濾過
膜２４，２５、腹水濃縮用の限外濾過膜２６，２
７から構成され、腹水入口２８が膜２４，２５に
囲まれた部屋に連絡するように取り付けられ、同
時に膜２４と２６および２５と２７の間を接着
し、液が洩れないようになつている。また、除
菌、除癌細胞され濃縮された腹水の出口３０が膜
２６と２７に囲まれた部屋に連絡するように接続
され、フラツシユ口２９が膜２４と２５に囲まれ
た部屋に連絡するように取り付けられている。さ
らに、円筒容器２３には限外濾過膜２６，２７か
らの濾液を排出するための出口３１が取り付けら
れている。また、腹水の入口２８およびフラツシ
ユ口２９は円筒容器２３の上蓋または下蓋（図示
しない）に導かれている。さらに膜と膜との間、
膜と容器との間にスペーサーを取り付けている
（図示しない）。 FIG. 4 is a schematic diagram of an example of an ascites filtration concentrator in which a filtration membrane is spirally wound into a cylindrical shape and housed in a cylindrical container. 25. Ultrafiltration membrane for ascites concentration 26,2
7, and the ascites inlet 28 is attached so as to communicate with the chamber surrounded by the membranes 24 and 25, and at the same time, the membranes 24 and 26 and 25 and 27 are bonded to prevent fluid from leaking. . Further, an outlet 30 of ascites, which has been sterilized, cancer cells removed, and concentrated, is connected to a chamber surrounded by membranes 26 and 27, and a flash port 29 is connected to a chamber surrounded by membranes 24 and 25. It is installed like this. Further, the cylindrical container 23 is provided with an outlet 31 for discharging the filtrate from the ultrafiltration membranes 26 and 27. Further, the ascites inlet 28 and flush port 29 are led to the upper or lower lid (not shown) of the cylindrical container 23. Furthermore, between the membranes,
A spacer is installed between the membrane and the container (not shown).
腹水は入口２８から導入され、除菌、除癌細胞
用の濾過膜２４，２５で濾過、除菌、除癌細胞さ
れ、膜２４，２５と膜２６，２７との間の部屋に
入る。ここで膜水濃縮用の限外濾過２６，２７に
より濃縮され、濃縮された蛋白質が出口３０より
導出される。 Ascites is introduced from the inlet 28, filtered through filter membranes 24 and 25 for sterilization and cancer-free cells, sterilized, and cancer-free, and then enters the chamber between the membranes 24, 25 and the membranes 26, 27. Here, the protein is concentrated by ultrafiltration 26, 27 for membrane water concentration, and the concentrated protein is led out from an outlet 30.
以上例をあげて述べたように、この発明によれ
ば装置の組み立て、滅菌、流体循環回路の接続等
に要する労力を非常に低減することが可能とな
り、形状寸法も非常に小さくすることができる。
すなわち、従来複数の回路を必要とした処理シス
テムを、１つのコンパクトなシステムとしてまと
めることができる。また、滅菌したものに手を加
えることなくそのまま使用できるので、安全性、
操作性の面での向上度は大きい。 As described above with examples, according to the present invention, it is possible to greatly reduce the labor required for assembling the device, sterilizing it, connecting the fluid circulation circuit, etc., and the shape and size can also be made extremely small. .
That is, a processing system that conventionally required multiple circuits can be combined into one compact system. In addition, since sterilized items can be used as is without any modification, safety and
The degree of improvement in terms of operability is significant.
第１図はこの発明の一例を示す装置の分解斜視
図であり、第２図は第１図の装置を組み立てたと
きの正面断面図であり、第３図は炭素繊維を組み
込んだ装置の例を示す正面断面図であり、第４図
は濾過膜を円柱状に巻いた装置の例の模式図であ
る。
３，１２，２４，２５……半透膜、５，１３，
２６，２７……半透膜、１６，１７……スペーサ
ー、１８……炭素繊維。
Fig. 1 is an exploded perspective view of a device showing an example of the present invention, Fig. 2 is a front sectional view of the device shown in Fig. 1 when assembled, and Fig. 3 is an example of a device incorporating carbon fibers. FIG. 4 is a schematic diagram of an example of a device in which a filtration membrane is wound into a cylindrical shape. 3, 12, 24, 25... semipermeable membrane, 5, 13,
26, 27... Semi-permeable membrane, 16, 17... Spacer, 18... Carbon fiber.
Claims (1)
濾過膜と、電解質を透過し、蛋白質を透過しない
限外濾過膜とが、お互いにその片面を対向させて
１つの部屋を形成し、各々の膜のもう一方の面は
それぞれ独立した別の部屋を形成しており、蛋白
質を透過し、細菌、癌細胞を透過しない濾過膜の
一方の面が形成する部屋には腹水を導入する為の
腹水入口及び該濾過膜を透過しない物質を除去す
る為のフラツシユ口を有し、他方の面が形成する
部屋には濃縮腹水出口を有し、上記２つの部屋以
外の部屋には濾液排出口を有する事を特徴とする
腹水処理装置。1. A filtration membrane that is permeable to proteins but not permeable to bacteria or cancer cells, and an ultrafiltration membrane that is permeable to electrolytes but not permeable to proteins are formed with one side facing each other to form one chamber. The other side of the membrane forms separate separate chambers, and the room formed by one side of the membrane, which allows proteins to pass through but does not allow bacteria and cancer cells to pass through, is used to introduce ascites fluid. It has an inlet and a flush port for removing substances that do not pass through the filtration membrane, the chamber formed by the other side has a concentrated ascites outlet, and the chambers other than the above two chambers have a filtrate outlet. An ascites treatment device characterized by:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP298977A JPS5388670A (en) | 1977-01-17 | 1977-01-17 | Fluid treating apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP298977A JPS5388670A (en) | 1977-01-17 | 1977-01-17 | Fluid treating apparatus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5388670A JPS5388670A (en) | 1978-08-04 |
| JPS6125381B2 true JPS6125381B2 (en) | 1986-06-16 |
Family
ID=11544775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP298977A Granted JPS5388670A (en) | 1977-01-17 | 1977-01-17 | Fluid treating apparatus |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5388670A (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54126679A (en) * | 1978-03-24 | 1979-10-02 | Kuraray Co Ltd | Membrane type fluid treating device |
| FR2527467A1 (en) * | 1982-05-28 | 1983-12-02 | Rhone Poulenc Sa | SEMI-PERMEABLE MEMBRANE APPARATUS, USED MORE PARTICULARLY IN PLASMAPHERESE |
| IT1217332B (en) * | 1988-02-02 | 1990-03-22 | Dideco Spa | PROCEDURE FOR THE EXTRA-BODY TREATMENT OF ASCITIC LIQUID |
| JP4965212B2 (en) * | 2006-09-29 | 2012-07-04 | 旭化成メディカル株式会社 | Blood treatment filter |
| EP3388093B1 (en) * | 2008-11-14 | 2020-05-20 | KCI Licensing, Inc. | Fluid pouch, system, and method for storing fluid from a tissue site |
-
1977
- 1977-01-17 JP JP298977A patent/JPS5388670A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5388670A (en) | 1978-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5015388A (en) | Integrated device for the biospecific purification of a liquid containing cellular elements | |
| US4361484A (en) | Process for treating and/or removal of substances from liquid, especially whole blood | |
| US3734851A (en) | Method and device for purifying blood | |
| US3483867A (en) | Artificial glomerulus and a method for treating blood | |
| US9713668B2 (en) | Multi-staged filtration system for blood fluid removal | |
| US5858238A (en) | Salvage of autologous blood via selective membrane/sorption technologies | |
| US4013564A (en) | Multipurpose metabolic assist system | |
| US4083786A (en) | Apparatus for treating ascites | |
| US4228015A (en) | Plasma treatment apparatus | |
| US4031010A (en) | Combined dialyzer and adsorber unit | |
| EP0966980A3 (en) | Method of rapidly removing liposoluble target molecules from a colloidal solution and wash solution for such a method | |
| JPS6125381B2 (en) | ||
| JPH1071201A (en) | Hemocatharsis drainage regenerating device, hemocatharsis liquid circuit, and hemocatharsis device | |
| CN112739393A (en) | Sorbent cartridge for dialysate regeneration | |
| JPH0510104B2 (en) | ||
| US4436626A (en) | Capillary diaphragms for use in diafiltration | |
| EP0327005B1 (en) | Process for extracorporeal treatment of ascitic fluid | |
| RU2687921C1 (en) | Filtering element for separation and concentration of liquid media | |
| JPS6084110A (en) | Composite type filtering concentrator | |
| US4565626A (en) | Apparatus for blood treatment by pressing blood into treating material and then drawing it out | |
| EP0112094A1 (en) | Apparatus for blood treatment | |
| JPS5946610B2 (en) | Ascites treatment device | |
| JPH038226B2 (en) | ||
| GB2083761A (en) | A combination sorbent, dialyser | |
| JPS5827685A (en) | Sterilized water-making unit |